WebMay 1, 2024 · Although no conclusive efficacy data exist with the following schedules of Carboplatin, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over five consecutive daily pulse doses has resulted in … WebSep 18, 2024 · Cisplatin can be used as monotherapy or as part of a multi-drug regimen. Patients should have proper hydration while monitoring …
Cisplatin (Intravenous Route) Proper Use - Mayo Clinic
WebThe median follow‐up time was 31.5 months, with a deadline of August 2024 for the final follow‐up. At the time of our analyses, 27 patients were still alive, and 19 patients had no evidence of disease progression. Kaplan–Meier curves for OS, PFS, LRFS, and DMFS are shown in Figure 1. The 1‐, 2‐, and 3‐year OS rates were 84.6%, 64.1% ... WebDec 1, 2024 · Methods. In this open-label, randomized, phase III study, newly diagnosed patients with advanced NSCLC were initially randomized (R1, 1:1) to receive first-line treatment with cisplatin 75 mg/m 2 plus docetaxel 75 mg/m 2 (DC75) or 60 mg/m 2 (DC60) for up to 4 cycles. Patients without progression were further randomized (R2, 1:2) to best … tsw 3 scotrail
Cisplatin Article - StatPearls
WebApr 11, 2024 · According to the Food and Drug Administration, there are four cancer drugs in shortage: Pluvicto, for advanced prostate cancer, as well as methotrexate, cisplatin and fluorouracil, common chemotherapy drugs used to treat a broad range of cancers from the skin to the bones and lungs. A fifth drug, a bladder cancer therapy called BCG, is also ... WebPurpose: To evaluate the tolerability of four alternating cisplatin-gemcitabine schedules. A secondary aim was to evaluate the clinical efficacy of this combination. Patients and methods: Forty-one patients with advanced solid tumors received alternating sequences with a 4- and 24-hour interval of cisplatin and gemcitabine. . Gemcitabine 800 mg/m2 was … WebAug 1, 2024 · The recommended dose of Alimta when administered with cisplatin in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Renal Impairment tsw 3 release